精华制药
(002349)
| 流通市值：60.58亿 | | | 总市值：61.73亿 |
| 流通股本：8.14亿 | | | 总股本：8.30亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,092,285,389.95 | 731,420,574.35 | 363,535,559.83 | 1,402,088,293.43 |
| 营业收入 | 1,092,285,389.95 | 731,420,574.35 | 363,535,559.83 | 1,402,088,293.43 |
| 二、营业总成本 | 853,284,673.64 | 558,016,042.71 | 279,284,981.39 | 1,110,157,028.28 |
| 营业成本 | 517,097,102.69 | 339,310,270.71 | 175,127,814.59 | 705,568,874.92 |
| 税金及附加 | 17,520,095.27 | 11,739,390.83 | 5,690,601.14 | 20,823,343.48 |
| 销售费用 | 203,123,914.2 | 132,274,180.08 | 62,075,019.03 | 247,794,237.97 |
| 管理费用 | 91,880,233.18 | 57,664,195.89 | 30,642,077 | 118,929,822.02 |
| 研发费用 | 43,536,583.86 | 28,840,794.78 | 10,499,381.03 | 61,789,405.41 |
| 财务费用 | -19,873,255.56 | -11,812,789.58 | -4,749,911.4 | -44,748,655.52 |
| 其中:利息费用 | 456,819.92 | 461,853.97 | 228,985.49 | 1,335,484.11 |
| 其中:利息收入 | 22,054,939.82 | 12,852,938.48 | 5,101,522.93 | 44,008,856.13 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,121,088.82 | 1,451,220.5 | 782,312.56 | 3,816,186.27 |
| 加:投资收益 | 1,803,269.91 | 1,434,037.28 | 472,032.72 | 4,372,311.26 |
| 资产处置收益 | 38,903.55 | 28,384.68 | 23,905.98 | -202,291.53 |
| 资产减值损失(新) | -4,927,449.1 | -4,097,935.86 | -3,776,994.23 | -15,257,525.46 |
| 信用减值损失(新) | -513,963.56 | -829,088.08 | -518,188.18 | -3,404,161.92 |
| 其他收益 | 3,559,198.14 | 2,783,496.78 | 1,517,110.64 | 13,802,514.57 |
| 四、营业利润 | 242,081,764.07 | 174,174,646.94 | 82,750,757.93 | 295,058,298.34 |
| 加:营业外收入 | 1,157,227.88 | 987,323.68 | 760,227.89 | 3,199,057.13 |
| 减:营业外支出 | 191,572.56 | 26,870.12 | 1,154.91 | 4,939,013.38 |
| 五、利润总额 | 243,047,419.39 | 175,135,100.5 | 83,509,830.91 | 293,318,342.09 |
| 减:所得税费用 | 33,494,967.65 | 23,448,502.07 | 11,992,395.52 | 45,852,077.23 |
| 六、净利润 | 209,552,451.74 | 151,686,598.43 | 71,517,435.39 | 247,466,264.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 209,552,451.74 | 151,686,598.43 | 71,517,435.39 | 247,466,264.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 176,372,682.12 | 130,644,421.69 | 62,219,690.39 | 212,651,534.66 |
| 少数股东损益 | 33,179,769.62 | 21,042,176.74 | 9,297,745 | 34,814,730.2 |
| 扣除非经常损益后的净利润 | 170,110,974.04 | 126,621,740.94 | 60,349,142.87 | 195,897,114.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.21 | 0.16 | 0.08 | 0.26 |
| (二)稀释每股收益 | 0.21 | 0.16 | 0.08 | 0.26 |
| 九、综合收益总额 | 209,552,451.74 | 151,686,598.43 | 71,517,435.39 | 247,466,264.86 |
| 归属于母公司股东的综合收益总额 | 176,372,682.12 | 130,644,421.69 | 62,219,690.39 | 212,651,534.66 |
| 归属于少数股东的综合收益总额 | 33,179,769.62 | 21,042,176.74 | 9,297,745 | 34,814,730.2 |
| 公告日期 | 2025-10-30 | 2025-08-30 | 2025-04-30 | 2025-04-15 |
| 审计意见(境内) | | | | 标准无保留意见 |